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Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million 
people in the United States. Given that most patients are asymptomatic until late in disease 
progression, diagnostic screening and evaluation of patients that display high-risk behaviors 
associated with acquisition of hepatitis C should be performed. Chronic hepatitis C is associated 
with cirrhosis, hepatic failure and death, therefore treatment is aimed at reducing these 
complications as well as improving quality of life and minimizing adverse effects. The American 
Association for the Study of Liver Diseases Practice Guidelines on the Diagnosis, Management 
and Treatment of Hepatitis C represent the gold standard for guidance on the management of 
hepatitis C. Standard treatment for hepatitis C is peginterferon alfa in combination with ribavirin. 
Currently, two pegylated interferon products are approved by the U.S. Food and Drug 
Administration for the treatment of hepatitis C. The duration of therapy with peginterferon and 
ribavirin is currently dictated by viral genotype and virologic response. Additional therapies are 
currently under investigation for treatment of chronic hepatitis C and show early promise of 
comparative efficacy and reduced adverse effects. Special considerations in certain populations, 
including co-infection with human immunodeficiency virus, end-stage renal disease, injection 
drug use, pregnancy and pediatric patients should guide treatment decisions.   
  





Hepatitis C virus (HCV), a single-stranded RNA virus, is the most common chronic bloodborne 
illness in the United States. It is estimated that as many as 4 million people are chronically 
infected. Though reported surveillance data likely reflect accurate trends, it also likely 
underestimates the true burden of disease.1 HCV was officially recognized in 1989 and had 
previously been referred to as “non-A, non-B hepatitis.”2 The majority of patients who develop 
acute hepatitis C will develop chronic infection and as many as 30% of chronic HCV infections 
are from unknown causes.3 
The incidence rates of acute hepatitis C have declined since the 1980s and 1990s and have 
steadied since 2003, possibly as a result of increased education and public awareness of 
transmissible risk factors (Figure 1).1,4-5 Routine blood screening, implemented in 1992, has also 
contributed to the declining incidence. HCV rates in people aged 25-39 years, typically those 
with the highest rates of infection, have decreased 90% from 1990 to 2007. Additionally, the 
historically higher incidence in males is declining, with similar rates now reported in both sexes. 
Currently, the prevalence of chronic infection is highest in persons aged 40-49 years.  Rates 
during 2004-2007 were similar among racial/ethnic groups except for American Indians/Alaskan 
Natives, in which incidence rates increased.  Previous prevalence data showed higher rates in 
non-Hispanic blacks.1 
Complications & Economic Burden  
Given that the majority of patients living with chronic hepatitis C are relatively young and often 
asymptomatic, the future economic impact of associated complications is likely to be substantial. 
Cirrhosis, liver failure and hepatocellular carcinoma are possible complications of chronic HCV. 
As many as 20-30% of patients with chronic HCV will progress to cirrhosis within 20 years. 
Chronic viral hepatitis is a leading cause of hepatocellular carcinoma and one of the most 
common reasons for liver transplantation in the U.S.1 It is estimated that 12,000 deaths annually 
are a result of chronic liver disease due to hepatitis C infection.5 
One group of authors analyzed U.S. hospitalizations and prescription data over an 8 year period 
(1994-2001) to understand outcomes associated with hepatitis C. Hospitalization trends were 
analyzed using the Nationwide Inpatient Sample from the Healthcare Cost and Utilization 
Project where a 20% stratified sample of U.S. community hospitals was collected for data 
extrapolation. Outpatient data was obtained via the National Ambulatory Medical Care Survey 
and prescription data from Verispan Source Prescription Audit. ICD-9 codes were used for 
diagnoses. Though the average length of stay for liver-related hospitalizations associated with 
HCV decreased from 8.5 in 1994 to 6.9 in 2001, the number of hospitalizations more than 
doubled (111 vs. 244, respectively). Additional findings included that for every $100,000 spent 
in nationwide hospitalizations in 2001, $427 were due to liver-related complications from 
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hepatitis C, compared with $145 in 1994. Patients aged 40-49 accounted for more 
hospitalizations, greater expenditures and had a higher incidence of death than other age groups. 
Physician office visits by HCV patients and prescription drug expenditures also greatly 
increased.6 
Diagnosis 
The American Association for the Study of Liver Diseases (AASLD) Practice Guidelines on the 
Diagnosis, Management and Treatment of Hepatitis C represent the gold standard for guidance 
on the management of hepatitis C (Table 1).7  These guidelines were approved and are supported 
by the AASLD, the Infectious Disease Society of America, and the American College of 
Gastroenterology.7  
A laboratory diagnosis of HCV is determined after screening for possible risk factors and 
evaluation of signs and symptoms. Acute illness presents symptomatically in 20-30% of patients. 
Many patients chronically infected with HCV are asymptomatic or may exhibit only mild 
symptoms.8 Possible symptoms include abdominal pain, fever, fatigue, loss of appetite, nausea 
and vomiting.3,8-9  
Risk Factors 
HCV infection is transmitted by exposure to infected blood or blood products (Table 2).1-3,7,9-10  
Injection drug use (IDU) is the most common route of exposure to hepatitis C.1,7 All persons who 
report illicit drug use, including intranasal cocaine use should be screened for HCV.2,7 The 
prevalence of HCV reported in injection drug users is extremely high, with a proportional 
relationship to the length of drug use. Within 5 years of beginning injection drug use, 1 in 3 
persons will become infected with HCV.11  
Other populations at risk of HCV infection include individuals who received a blood or blood 
component transfusion prior to 1992, healthcare exposure, patients who ever received chronic 
hemodialysis, persons with human immunodeficiency virus (HIV), children of HCV-infected 
mothers, and persons with multiple sexual partners, although transmission between monogamous 
partners is uncommon (see Table 2).1-3,7,9-10 The risk of HCV transmission between monogamous 
sexual partners is less than 1%.3 Persons who have ever been on chronic hemodialysis, those 
with unexplained abnormal aminotransferase levels or  infected with HIV are considered at risk 
due to the higher prevalence of infection in these patients.7 Less than 5% of infants born to HCV-
infected mothers will acquire the infection.3 Additionally, breastfeeding has not been linked to 
transmission of HCV.3,7 Though exposure via tattooing, acupuncture and body piercing is 
possible, each has rarely been reported as the sole possible mode of transmission.2-3,7,9  
Several risk factors are associated with progression to chronic disease. Nonmodifiable risk 
factors include increased age at the time of initial infection, male gender, race and genetic factors 
linked to polymorphisms of specific genes involved in the rate of fibrosis and hepatocellular 
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carcinoma. Though African-American patients display a higher rate of development of 
hepatocellular carcinoma, a lower response to therapy and higher liver-related mortality as 
compared to whites, studies have shown they are actually less likely to progress to cirrhosis. 
Limited evidence shows that Latino patients, on the other hand, progress faster to cirrhosis 
compared to whites. Potentially modifiable risk factors include alanine aminotransferase levels 
(ALT), alcohol intake, smoking, and co-infection with HIV or hepatitis B virus (HBV).10  
Clinical features of disease progression to cirrhosis may include jaundice, enlarged liver and/or 
spleen, muscle wasting and ascites. Elevated alkaline phosphatase, gamma glutamyl 
transpeptidase and aspartate aminotransferase (AST) may also be seen. Low platelet and white 
blood cells may also be observed. Extrahepatic manifestations are uncommon but can include 
cryoglobulinemia, glomerulonephritis and porphyria cutanea tarda.3 
The diagnosis of chronic HCV is established when anti-HCV is present and serum 
aminotransferase levels remain elevated for ≥6 months.3,7 Polymerase chain reaction (PCR) 
testing for HCV RNA will establish the diagnosis and is indicative of current and active 
infection.   
Laboratory Testing  
Both qualitative and quantitative tests are utilized in the diagnosis of HCV. Anti-HCV confirmed 
by enzyme immunoassay (EIA) is the initial serologic test used to establish exposure to HCV but 
is not necessarily indicative of current infection. The current EIAs available have specificity 
greater than 99%. Current infection can be established with quantitative analysis of HCV RNA 
via PCR or transcription-mediated amplification. Currently available PCR assays have excellent 
specificity (98 to 99%) and will detect HCV RNA in the serum to a lower limit of 50 to 100 
copies/milliliter (mL). Most patients with chronic HCV will have levels of HCV RNA (viral 
load) between 100 000 (105) and 10 000 000 (107) copies per mL (or 50 000 to 5 million 
international units [IU]/mL). Laboratory interpretation of anti-HCV and HCV RNA for diagnosis 
is described in Table 3.3,7 
Confirmatory testing is essential in high risk patients testing negative for anti-HCV. 
Immunocompromised patients, including those with HIV, solid organ transplant recipients or 
those receiving hemodialysis, may test as false-negative due to the inability to mount a sufficient 
immune response. Likewise, persons with acute HCV infection may require up to 1 month or 
more for adequate antibody detection. Follow-up and/or confirmatory testing of HCV RNA for 
these patients may be warranted (Table 3).3,7 Retesting for both anti-HCV and HCV RNA in 4 to 
6 months may help to resolve issues with false-positive and false-negative results.3,7 
In June 2010, the FDA approved the first rapid blood test for antibodies to HCV (OraQuick® 
HCV Rapid Antibody Test, OraSure Technologies). It is approved for use in patients’ ages 15 
years and older. The test is approved for screening in persons who are considered at risk for 
Chronic Hepatitis C & Current Therapies 6 
 
 
HCV infection and works from a sample of venous blood with readable results in about 20 
minutes.12-13 
ALT and AST tests may appear normal or elevated in chronic infection. Elevations in ALT are 
more frequently seen, usually less than 5 but as high as 20 times the upper limit of normal.3 
Liver biopsy is not needed to diagnose HCV but is useful in determining the grade and stage of 
liver disease. The grade of disease is determined by evidence of necrosis and inflammation in 
liver tissue whereas the stage is determined by the extent and presence of fibrosis and cirrhosis. 
At this time, the decision to obtain a liver biopsy for prognostic purposes or to guide a decision 
for treatment should be individualized taking into consideration the probability of disease 
progression, patient willingness to undergo the procedure and genotype.3,7 
Genetic Variations 
Six different genotypes and more than 50 subtypes exist for HCV. Genotype denotes nucleotide 
variation and is typically represented geographically by location for HCV. Genotype 1 is the 
most common in the U.S. followed by genotypes 2 and 3. Genotype 4 is most represented in the 
Middle East, including, Egypt and Africa whereas genotype 5 is seen in South Africa, and 
genotype 6 in Southeast Asia.14-15 Genotypic variations aid in identifying patients likely to 
respond to treatment and guide the duration of therapy, so it is important to guide therapeutic 
decisions.3,7 
Therapeutic Management 
The management of chronic HCV should be individualized. Methods to prevent transmission and 
the importance of adherence to treatment should be addressed. Treatment is strongly 
recommended and should be considered in patients with chronic HCV and detectable levels of 
HCV RNA, elevated aminotransferase levels and histologic evidence of progressive liver 
disease.7,16 
The primary goals of therapy are to prevent complications and death from HCV while reducing 
adverse events and maintaining quality of life. The difficulty in achieving these goals is 
complicated by the slow progression of chronic disease and treatment responses that are based on 
surrogate virological parameters versus long-term clinical outcomes. Normalization of serum 
aminotransferase levels, virologic response and histological improvement are several short-term 
outcomes commonly assessed.7 
“Virologic cure” is established by a sustained virologic response (SVR), defined as the absence 
of serum HCV RNA by PCR assay 24 weeks following cessation of therapy.7 SVR offers the 
best prediction of long-term response. Lack of an early virologic response (EVR) can be used to 
predict non-responders and a lack of SVR. Evaluation of rapid virologic response (RVR) can be 
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used to assess durations of treatment based on genotype. All possible virologic responses are 
defined in Table 4.7  
Alfa interferon or interferon alfa-2b (Intron A, Schering Corp., 1986) was the first therapy 
approved for the treatment of HCV.17 The limitations with this standard, non-pegylated 
interferon included rapid absorption in subcutaneous tissue, a large volume of distribution, rapid 
renal elimination, a short half-life and variable peak-trough concentrations.16 These unfavorable 
characteristics necessitated dosing three times weekly. The later addition of a polyethylene 
glycol (pegylated) moiety resolved many of these issues. Ribavirin, an oral synthetic nucleoside 
analogue, acts synergistically with pegylated interferon is administered in divided doses. 
Ribavirin is not effective or indicated as monotherapy for treatment of HCV.18 The combination 
of pegylated interferon and ribavirin represent the current recommendations for the treatment of 
HCV.  
Safety 
Treatment-limiting adverse effects are a common complication HCV treatment and are 
experienced by most patients. Adverse events may lead to dosage reductions or treatment 
discontinuation. The most common side effects (incidence varies, 20-40%) include flu-like 
effects (fatigue, headache, fever), gastrointestinal effects (nausea, anorexia, diarrhea) and 
psychiatric effects (irritability, depression, insomnia). Psychiatric effects can be managed with 
frequent assessment and counseling. Selective serotonin reuptake inhibitors can be used to treat 
depression. Agent selection should address hepatic dysfunction and drug interactions. Laboratory 
abnormalities such as neutropenia (absolute neutrophil count [ANC] <1500 mm3) and anemia 
also frequently lead to dosage reductions and/or treatment discontinuation. The use of 
granulocyte colony stimulating factors is usually not necessary except in cases of advanced 
cirrhosis. Likewise, growth factors such as erythropoietin and darbepoietin should be used 
cautiously in light of the potential for serious cardiac and thromboembolic events and increased 
costs. Their use has not been associated with better clinical outcomes in HCV, including 
attainment of SVR.7,18-20 
Significant safety concerns exist with all interferon products. A black box warning highlights the 
potential for causing or aggravating fatal or life-threatening neuropsychiatric, autoimmune, 
ischemic and infectious disorders. Patients require careful monitoring and observation while 
receiving these therapies. Therapy should be discontinued in patients with persistently severe or 
worsening signs or symptoms of any of the mentioned conditions. Contraindications to the use of 
interferon include hepatic decompensation as evidenced by a Child-Pugh score of >6 (Class B or 
C) in cirrhotic patients before or during treatment. Routine monitoring of complete blood counts 
(CBC) and liver function tests (LFTs), including pre-treatment and routinely thereafter is 
necessary. Dosage reductions should be considered in patients with hematologic abnormalities, 
moderate depression, renal dysfunction or if transaminase levels flare. Severe depression 
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warrants discontinuation of therapy. Individual prescribing information should be consulted for 
specific recommendations for dosage reductions associated with each alfa interferon product.19-20  
Ribavirin carries a black box warning regarding its potential to cause birth defects and fetal 
death. It is rated as Pregnancy Category X and is contraindicated in pregnant women and men 
whose female partners are pregnant. Women of childbearing age and men must use 2 effective 
forms of contraception during the treatment period and for 6 months following treatment. 
Routine monthly monitoring of pregnancy tests is also required. A toll-free hotline to a Ribavirin 
Pregnancy Registry was established to monitor maternal and fetal outcomes of pregnant women 
exposed to ribavirin.19-20 
Other serious effects with ribavirin highlighted in a black box warning include the risk of 
hemolytic anemia which may result in worsening cardiac disease. Because of the risk of 
hemolytic anemia, a CBC should be obtained pretreatment and at a minimum, weeks 2 and 4 of 
therapy. Patients with pre-existing cardiac disease need to have an echocardiogram before 
treatment and should be closely monitored. Dosage reductions are determined by laboratory 
values, specifically for anemia in the presence or absence of cardiac history. Ribavirin is also 
contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the 
formulation and should not be used in patients with a creatinine clearance (CrCl) <50 mL/min.18 
Current Treatment Regimens 
All patients with chronic HCV should be evaluated for treatment with peginterferon and 
ribavirin. Depending on HCV genotype, the duration of therapy will be determined. Patients with 
genotype 1 infection typically have an SVR rate varying around 40 to 55%, whereas those with 
genotypes 2 or 3 have higher rates at 70 to 90%.21-22 Genotypes 1 & 4 require treatment for 48 
weeks while those with genotype 2 or 3 can receive 24 weeks of therapy.7 Given the complexity 
and breadth of literature in patients receiving retreatment of HCV post liver transplantation, 
studies focused in that area of practice are not included in the scope of this review. 
Recent clinical studies evaluating various treatment strategies are summarized in Tables 5 and 
6.23-38  Most studies were conducted in treatment naïve patients with detectable HCV RNA, 
histologic findings consistent with chronic HCV and elevated ALT levels. Study analyses were 
conducted as intention-to-treat unless otherwise noted. All studies were approved by institutional 
review or in accordance with the Helsinki Declaration of 1975. 
Comparative Efficacy of Pegylated Interferons 
Currently, two pegylated interferons are FDA approved for treatment of HCV, peginterferon 
alfa-2a (Pegasys, Hoffman-La Roche, 2002) and peginterferon alfa-2b (Peg-Intron, Schering 
Corp., 2001).17 Though both agents are routinely prescribed for treatment, their dosing regimens 
and pharmacokinetics differ. Peginterferon alfa-2b is dosed according to body weight, whereas 
peginterferon alfa-2a is a fixed dose. Both regimens are dosed subcutaneously once weekly; 
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however, their half-lives are different. Peginterferon alfa-2b has a 40 hour mean elimination half-
life, and peginterferon alfa-2a has a plasma half-life ranging from 80 to 160 hours.19-20 These 
differences in half-lives have corresponded to reduced or absent plasma concentrations at 7 days 
and variable peak-trough ratios with peginterferon alfa-2b.23 Until recent studies, it was uncertain 
whether these differences significantly impacted treatment outcomes. The efficacy and safety of 
both pegylated interferons have been studied in several recent prospective, randomized, clinical 
trials (Table 5).23-33 Standard dosing of peginterferon alfa-2a at 180 µg and peginterferon alfa-2b 
at 1.5 µg/kg subcutaneously once weekly were utilized in all studies unless otherwise noted.  
Di Bisceglie et al.23 conducted a prospective, randomized open-label study to compare viral 
kinetics and HCV RNA response at 12 weeks between peginterferon alfa-2a and peginterferon 
alfa-2b in combination with ribavirin. Patients with genotype 1 and viral load ≥ 800 000 IU/mL 
were evaluated. Weight-based dosing of ribavirin (1000 and 1200 mg for weights ≤75 kg and 
>75 kg, respectively) was used. Standard dosing of peginterferon alfa-2a and peginterferon alfa-
2b was utilized. The primary endpoint, HCV RNA over time, was comparable between both 
groups at all time points. Similarly, the number of patients who achieved RVR was similar. More 
patients withdrew treatment in the peginterferon alfa-2b arm (5.7% vs. 1%) for safety reasons 
such as rash, anemia, suicidal ideation, depression, influenza-like symptoms, among various 
others. However, no significant differences in overall safety outcomes were noted. The 
peginterferon alfa-2b group experienced more influenza-like illness, chills, fever, rash and 
vomiting, whereas the peginterferon alfa-2a group had more dyspnea reported.  Neutropenia 
(Grade 3 or greater) occurred in 43.4% of patients in the peginterferon alfa-2a group vs. 34.8% 
in the peginterferon alfa-2b group.  
Another study compared peginterferon alfa-2a and peginterferon alfa-2b for differences in SVR 
in treatment-naïve patients with chronic HCV.24 This was a prospective, randomized open-label 
study. Weight-based ribavirin was utilized (<65 kg: 800 mg/day; 65-75 kg: 1000 mg/day; >75 
kg: 1200 mg/day). The duration of treatment was 24 weeks for genotypes 2/3 and 48 weeks for 
genotypes 1/4. Results showed that SVR rates were similar among groups, 65.9% in the 
peginterferon alfa-2a arm and 62% with peginterferon alfa-2b (p=0.64). Differences between 
genotypes according to treatment group were also not significant with more than 45% of 
genotype 1 achieving SVR and more than 80% of genotypes 2/3 and 4.  
A third arm of the Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated 
Interferon Therapy (IDEAL) study was undertaken to evaluate the safety and efficacy of 
standard peginterferon alfa-2a, standard peginterferon alfa-2b, and low-dose peginterferon alfa-
2b in 3070 treatment-naïve patients with genotype 1 HCV.25 Low-dose peginterferon alfa-2b 
consisted of 1.0 µg/kg weekly. All regimens were in combination with weight-based ribavirin; 
however, the dose differed according to which interferon product was used. Ribavirin was dosed 
in the following manner for peginterferon alfa-2b: 40-65 kg: 800 mg/day; >65-85 kg: 1000 
mg/day; >85-105 kg: 1200 mg/day; >105-125 kg: 1400 mg/day. Peginterferon alfa-2a received 
ribavirin 1000 mg/day for weight <75 kg and 1200 mg/day for weight ≥75 kg. Different ribavirin 
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regimens were utilized based on the current prescribing information at the time of the study. The 
treatment duration was 48 weeks. The primary endpoint was SVR and two superiority analyses 
were conducted comparing the two dosage regimens of peginterferon alfa-2b and standard 
peginterferon alfa-2b vs. peginterferon alfa-2a. 
Rates of SVR were similar among all three groups [39.8% for standard peginterferon alfa-2b; 
38% for low-dose peginterferon alfa-2b (p=0.20); 40.9% for peginterferon alfa-2a (p=0.57)]. 
Adverse events were also similar in type and frequency between all groups. Two deaths were 
considered to be possibly related to treatment, one with standard peginterferon alfa-2b (suicide) 
and one with peginterferon alfa-2a (myocardial infarction).25   
Duration of Therapy According to Genotype 
Given that peginterferon and ribavirin represent the established treatment for chronic HCV, 
much of the current research focuses on duration of therapy. Genetic differences have been 
heavily studied in relation to HCV. The standard of evidence-based care has been to treat HCV 
patients with genotype 1/4 for 48 weeks and genotypes 2/3 for 24 weeks. More recently, studies 
have focused on individualizing the duration according to RVR or EVR. The following studies 
highlight some of these recent findings. 
Analysis of common predictors of SVR response was conducted in several of these studies.  
Factors such as age ≤45 years, genotype 2, baseline HCV RNA level ≤ 400 000 IU/mL, weight 
≤80 kg, ALT levels, and degree of fibrosis were all predictive of SVR.26,28-30,32 
Factors to consider with many of these studies is that though overall SVR rates may not differ, 
relapse rates and rates of discontinuation may be balancing the results. This, in addition to 
differences in study design may be contributing to the lack of consistent results regarding the 
optimal durations of treatment according to genotype. 
Genotype 1 
A prospective, open-label German study of genotype 1 patients randomized to standard 
peginterferon alfa-2a in addition to ribavirin (800 mg/day) for either 48 (Group A) or 72 weeks 
(Group B) aimed to evaluate differences in SVR and relapse rates.26 The study utilized fixed-
dose ribavirin. The primary efficacy measure, SVR, was similar in both groups (53% for 48 
weeks, 54% for 72 weeks, p=0.8), highlighting that duration of therapy did not translate into 
higher SVR rates. In addition, significantly more patients in Group B prematurely discontinued 
therapy (p<0.001).  
Patients who had detectable HCV RNA levels at week 12 achieved significantly higher SVR 
rates with 72 weeks of treatment vs. 48 (29% and 17%, respectively, p=0.04) whereas those who 
had undetectable levels at weeks 4 or 12 reached SVR rates as high as 84%, independent of 
treatment duration. This demonstrated that patients considered “slow responders” to therapy, 
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may benefit from extended treatment. Benefits of extended treatment on relapse rates were also 
noted in other patients who were considered slow responders (HCV-RNA detectable at weeks 4 
or 12) but HCV-RNA undetectable at week 12 (37% vs. 23%, Groups A and B, respectively, 
p=0.016) and week 24 (64% vs. 40%, Groups A and B, respectively, p=0.021). Rates of relapse 
were similar between groups (Group A, 29% and Group B, 21%, p=0.13). Adverse events did 
not differ between both treatment groups; however, more patients treated for 72 weeks 
discontinued therapy as compared to 48 weeks.26 
A similar study was conducted in the U.S. to evaluate extended treatment (48 vs. 72 weeks) in 
treatment naïve, genotype 1 patients treated with peginterferon alfa-2b in combination with 
weight-based ribavirin (≤64 kg: 800 mg; 64-84 kg: 1000 mg; 85-104 kg: 1200 mg; ≥105 kg: 
1400 mg).27 Before randomization, patients were determined to be slow responders, defined as at 
least a 2-log reduction in HCV RNA and undetectable levels at week 24. The primary endpoint, 
SVR, was statistically higher in the extended treatment arm receiving 48 weeks of additional 
treatment (38%) versus those treated for an additional 24 weeks (18%, p=0.03). A lower relapse 
rate was also found with the extended duration (20% vs. 59%, p=0.004). Adverse effects or rates 
of discontinuation did not differ significantly among groups.  
A noninferiority study conducted in Italy evaluated the efficacy of peginterferon alfa-2a or 
peginterferon alfa-2b combined with ribavirin in standard vs. extended treatment in patients with 
genotype 1.28 Weight-based ribavirin was dosed at 1000 mg/day for patients weighing ≤75 kg 
and 1200 mg if weight was >75 kg. Patients were randomized to 48 weeks of therapy or to an 
individualized duration based on virologic response during the initial 12 weeks of therapy. 
Patients in the individualized group who achieved RVR were treated for 24 weeks, and those 
achieving undetectable HCV RNA levels at 8 and 12 weeks were treated for 48 and 72 weeks, 
respectively.  
Sustained virologic response rates occurred in 45.1% of patients in the standard group and 48.8% 
in the individualized group (p=0.37). This met the criteria for establishing noninferiority. 
Patients who achieved RVR had SVR rates of 87% after 48 weeks of treatment and 77.2% after 
24 weeks of treatment in the individualized group (p=0.12). Patients achieving undetectable 
HCV RNA levels at week 12 showed a greater overall SVR response when randomized to the 72 
week duration rather than 48 weeks (63.4% vs. 38.1%, respectively). Relapse rates, adverse 
events, and virologic responses according to duration and peginterferon were also similar. More 
patients in the individualized group discontinued therapy. The authors concluded that these 
findings warrant larger studies to determine the benefit of individualized therapy based on 12 
week response.28 
Lastly, a study in patients with genotype 1 or 4 to evaluate a 24 week regimen after achieving 
RVR was conducted in Austria and utilized peginterferon alfa-2a in combination with ribavirin 
(1000-1200 mg/day).29 Patients who achieved RVR were assigned to 24 weeks of therapy. 
Results showed overall SVR rates of 76.7%. These results were the first reported of a larger 
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study involving 516 patients that will also evaluate treatment durations of 24, 48 and 72 weeks 
dependent upon virologic response.  
Cumulatively, the results of these recent studies recognize possible alternative durations of 
therapy in HCV genotype 1 patients, dependent upon virologic response, both RVR and EVR. 
For slow responding patients, commonly determined by week 12 and 24, a longer duration of 
treatment, up to 72 weeks, may be beneficial. Those patients with genotype 1 who achieve RVR 
may be candidates for 24 weeks of treatment. However, more conclusive evidence and larger 
studies need to be conducted to confirm these findings.  
Genotype 2/3 
Several small studies have found SVR rates of 80% or higher in patients with genotype 2/3 HCV 
after achieving RVR at 4 weeks and being treated with 12 to 16 weeks of therapy.39-42 
Differences in these studies, including treatment duration, ribavirin dosing, population 
characteristics and study design have made it difficult to use these findings as evidence to 
support a shortened duration of therapy for these patients. Though the concept of a shortened 
duration based on genotype and virologic response aims at reducing unnecessary treatment and 
adverse effects, some recent studies have shown attenuated efficacy when compared to the 
standard 24 weeks of therapy.   
A 2008 study sought to compare the efficacy of 12 or 24 weeks of therapy in patients with 
genotype 2/3.31 This was a randomized, open-label, phase III, multicenter study. Peginterferon 
alfa-2a and ribavirin 800 mg daily were administered. Results showed that 12 weeks of therapy 
was inferior to 24 weeks in relation to SVR rates (59% vs. 78%, respectively, p<0.0001). Also, a 
higher relapse rate was noted with 12 weeks (33% vs. 12%, p<0.0001). Adverse events leading 
to discontinuation of therapy occurred more frequently in the 24 week arm (p<0.0001).  
Another study randomized patients with genotype 2/3 to receive peginterferon alfa-2b in 
combination with weight-based ribavirin (<65 kg: 800 mg/day; 65-85 kg: 1000 mg/day; 86-105 
kg: 1200 mg/day; >105 kg: 1400 mg/day) for a treatment duration of 14 or 24 weeks dependent 
upon virologic response.32 Patients who achieved RVR were randomized to either 14 (Group A) 
or 24 weeks (Group B) of treatment, and patients not achieving RVR received 24 weeks (Group 
C) of therapy. This was an open-label, noninferiority study to evaluate SVR. Noninferiority 
could be established if the upper limit of the 95% CI was below the margin of 10%. The majority 
(80%) of patients were infected with genotype 3. Results showed that Group A had an SVR rate 
of 81.1% and Group B achieved SVR in 90.7% (95% CI, 1.7-17.7), not establishing 
noninferiority. When adjusted to include only patients with HCV RNA determination 24 weeks 
after the end of treatment SVR rates were similar (86.3% in Group A and 93.2% in Group B). 
Patients in Group A experienced higher relapse rates over Group B (10.8% vs. 5.3%), but Group 
B had higher rates of discontinuation. The incidence of adverse effects did not differ 
significantly between groups. 
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The Accelerate Trial is the largest study to date regarding shortened duration in genotypes 2 or 3. 
Efficacy was assessed in this large, international study conducted in 1469 patients.30 Patients 
were randomized to receive 16 or 24 weeks of therapy with peginterferon alfa-2a and ribavirin 
(400 mg twice daily). The study was designed as a per-protocol, noninferiority analysis with a 
margin for noninferiority set at 6%. Overall results failed to demonstrate noninferiority. 
Sustained virologic response rates were 65% in the 16 week group as compared to 76% in the 24 
week group (p<0.001). A significantly higher relapse rate occurred in the 16 week group as well 
(31% vs. 18%), p<0.001). Anemia and neutropenia were the most common cause of dose 
reductions. More patients in the 24 week group required dose reductions in ribavirin (23% vs. 
17%, p=0.01).  
Genotypes 4/5 
Few robust studies solely conducted in patients with genotype 4 and 5 exist. Though genotypes 1 
and 4 are thought to be similar, a recent prospective, uncontrolled study in 30 patients from the 
Middle East with genotype 4 demonstrated that treatment with peginterferon alfa-2a in 
combination with weight-based ribavirin (1000 mg/day for patients weighing <75 kg and 1200 
mg if weight was >75 kg) for 48 weeks resulted in a SVR in 63.6% of patients which was 
slightly higher than normally observed SVR rates for genotype 1.15 
A 2008 study conducted in Syrian patients with genotype 5 retrospectively evaluated 26 patients 
who received ribavirin (1000 to 1200 mg/day) in combination with interferon alfa-2a (3 million 
units three times weekly) or peginterferon alfa-2a at standard dosages. Patients were treated for 
24 or 48 weeks. More patients received standard interferon (65%) vs. pegylated interferon 
(35%). Results showed SVR was attained in 47% of patients with interferon vs. 67% with 
pegylated interferon (p=0.43). Higher rates were also achieved with 48 weeks of treatment.43 
Genotype 6 
Limited evidence exists regarding the appropriate duration of therapy for patients with genotype 
6. One small, retrospective cohort study was conducted to evaluate peginterferon in addition to 
ribavirin for 24 or 48 weeks in this population.33 The dosing schema was a) interferon alfa-2b (3 
million units three times weekly) in combination with ribavirin (1000 mg/day) b) weight-based 
peginterferon alfa-2b (80-150 µg) with weight-based ribavirin (800-1200 mg/day) or c) 
peginterferon alfa-2a (180 µg weekly) with ribavirin (1000-1200 mg/day) . In total, 23 patients 
were treated for 24 weeks and 12 patients completed 48 weeks. The majority of patients were 
Asian-American. Results showed SVR rates of 39% vs. 75% for those treated for 24 and 48 
weeks, respectively (p=0.044). The results of this study need to be confirmed with larger, 
prospective studies in this population.  
Overall the results of studies in patients with HCV genotype 2, 3 or 6 indicate that treatment 
duration of 24 weeks remains the most appropriate. Shorter durations are associated with relapse 
and lower SVR rates.  
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Relapsers and Non-Responders 
Patients who do not respond to the current standard of therapy have been less studied. Early 
studies evaluated clinical response to peginterferon in addition to ribavirin after failing treatment 
with interferon, and more recent studies aim to evaluate retreatment following treatment failure 
with pegylated interferon.44 Current U.S. guidelines do not strongly advocate retreatment of 
patients who previously fail to respond to initial therapy.7 Though consistent results are lacking 
and need to be confirmed with larger studies, potential situations for retreatment exist, including 
in those patients who previously failed therapy with non-pegylated interferon. 
The EPIC Study (Evaluation of PegIntron in Control of Hepatitis C) was a large, international, 
multicenter, open-label study conducted to evaluate the retreatment of patients with chronic 
HCV who previously failed therapy with peginterferon or non-pegylated interferon therapy in 
combination with ribavirin.45 Patients qualified for retreatment if they presented with significant 
hepatic fibrosis or cirrhosis and needed to receive at least 12 weeks of combination therapy 
without achieving SVR. Patients received standard peginterferon alfa-2b in combination with 
weight-based ribavirin for 48 weeks. The majority of patients were Caucasian males with 
genotype 1 HCV, viral loads > 600 000 IU/mL, and were nonresponders to previous treatment 
with interferon therapy in combination with ribavirin. Overall, 22% of patients achieved SVR 
with a greater response observed in relapsers vs. non-responders (38% vs. 14%, respectively) 
regardless of previous treatment. Furthermore, patients who previously received interferon 
therapy responded better than those who received pegylated interferon (25% vs. 17%, 
respectively). Genotype, viral load at baseline, stage of fibrosis, previous treatment regimen and 
previous response were found to be significant predictors of response.   
Extending the treatment duration of therapy may be a viable option in HCV non-responders 
following treatment with peginterferon and ribavirin. One study was conducted to investigate the 
use of peginterferon alfa-2a with ribavirin to retreat non-responders to peginterferon alfa-2b in 
combination with ribavirin.46 This parallel-group, international study randomly assigned patients 
to 1 of 4 possible open-label treatment groups. Group A received peginterferon alfa-2a, 360 
µg/week for 12 weeks followed by 180 µg/week to complete 72 weeks of treatment or 48 weeks 
of treatment (Group B). Group C received peginterferon alfa-2a, 180 µg/week for 72 weeks or 48 
weeks (Group D). All patients received ribavirin (1000 or 1200 mg daily). The majority of 
patients had genotype 1. The rate of SVR in Group A was 16% vs. 9% in Group D (p=0.006). 
SVR rates were 7% in Group B and 16% in Group C. More patients in treatment Group A and C 
benefited from extended durations but withdrew treatment early. Additionally, the overall rate of 
serious adverse events was higher in patients assigned to 72 weeks of therapy. The results of this 
study demonstrated the possibility of extended treatment in non-responders to peginterferon 
therapy; however, the withdrawal rate and risk of adverse events needs to be considered.  
Patients who relapse or those who do not respond to initial peginterferon and ribavirin therapy 
need to be adequately assessed prior to initiating retreatment. Previous response (non-response, 
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relapse, and breakthrough) needs to be assessed. Also, modifiable risk factors affecting treatment 
should be identified, including adherence to treatment, body weight and alcohol abuse.44  
Alternative and Investigational Therapies 
Several new therapies are in development for the treatment of HCV (Table 6).34-38Additionally, 
targeted HCV inhibitors are promising agents for future treatment.47 
Albinterferon 
A new interferon product, albinterferon, consists of interferon alfa-2b genetically fused to 
recombinant human albumin, allowing for a more convenient dosing schedule (once or twice 
monthly).34,47 Albinterferon alfa-2b is an 85.7 kilodalton (kDa) protein with an estimated half-
life of 150 hours.34-35 Albinterferon is currently in phase I studies in the U.S. for the treatment of 
HCV in patients with HIV co-infection. No studies have evaluated use of albinterferon in 
patients with renal dysfunction. Several other countries are in phase III of development for the 
use of albinterferon as combination therapy in treatment naïve patients with HCV.48  
An open-label, phase III, multicenter trial investigated dosing strategies, efficacy, safety and 
patient reported health-related quality of life (HRQOL) of albinterferon alfa-2b compared to 
peginterferon alfa-2a in previously untreated patients with genotype 1.34 Patients were 
randomized to 1 of 4 treatment groups, including albinterferon 900 µg subcutaneously once 
every 2 weeks, albinterferon 1200 µg once every 2 weeks, albinterferon 1200 µg once every 4 
weeks or active control, or peginterferon alfa-2a 180 µg subcutaneously once weekly. In 
addition, all patients received weight-based ribavirin (1000 mg/day if <75 kg or 1200 mg/day if 
≥75 kg). The duration of treatment was 48 weeks. 
Results of the primary and secondary efficacy endpoints, including SVR, relapse rate, and 
breakthrough rate demonstrated no significant difference between the albinterferon groups and 
peginterferon alfa-2a. SVR ranged from 55 to 58% in the intention-to-treat analysis of all groups 
(p=0.64) Rates of adverse events were similar among all groups with the exception of the 
albinterferon 1200 µg every 2 week group, which experienced a higher rate and more severe 
adverse effects. Rates of discontinuation were also higher in this group (p=0.04). Hematologic 
abnormalities were comparable across groups except for the albinterferon 1200 µg every 4 week 
group, which had significantly lower rates of events (p<0.05). Health-related quality of life was 
significantly favorable in the albinterferon 900 µg every 2 week treatment group as compared to 
peginterferon alfa-2a in terms of scores and missed workdays (p<0.05).34 
Another phase II, open-label, multicenter trial conducted in 43 treatment naïve patients with 
genotypes 2/3 was aimed at evaluating the safety of different dosages of albinterferon alfa-2b in 
combination with ribavirin.35 In contrast to the previous study, a higher dosage of albinterferon 
was utilized (1500 µg) every 2 or 4 weeks. In addition to assessing efficacy and safety, this study 
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sought to determine if an association exists between insulin resistance and antiviral response in 
patients with genotype 2/3. The treatment duration was 24 weeks. 
Rates of SVR were 77.3% for the every 4 week treatment arm versus 61.9% for the every 2 week 
arm (p=0.27). The lower response in the every 2 week arm was attributed to a higher 
discontinuation rate unrelated to treatment. Insulin resistance, estimated by homeostasis model 
assessment of insulin resistance (HOMA-IR), was determined if the HOMA-IR score was >2. 
Patients who demonstrated insulin resistance according to these methods exhibited a lower SVR 
as compared to those patients without insulin resistance (42.9% and 88.2%, respectively, 
p=0.02).35 
No significant differences were found between both dosage regimens in terms of safety and 
tolerability. Some of the most frequently reported moderate-severe adverse events included 
headache, fatigue, chills, myalgia, nausea, pyrexia, decreased weight, back pain, altered mood 
and arthralgia which did not different significantly between groups. Hematologic abnormalities 
did not differ; however, a greater incidence of lower ANC was found in the 1500 µg every 2 
week treatment group as compared to the every 4 week group (23.8% versus 9.1%, respectively, 
p=0.24). No reductions in hemoglobin <10 g/dL or platelet counts < 50 000/mm3 occurred. 
Additionally, no patients in the every 4 week treatment arm required dosage reductions due to 
hematologic effects.35 
Taribavirin 
Taribavirin, a prodrug of ribavirin, is also being studied for the treatment of chronic HCV with 
the benefit of a lower incidence of anemia.47,49 The major conversion site of taribavirin is in the 
liver, enabling this drug to concentrate in this location. Taribavirin contains a positively charged 
3-carboxymide group, which prohibits its uptake in red blood cells and is thus associated with 
less hemolytic anemia.36,49-50 Taribavirin is currently in phase II testing in the U.S. for treatment 
of chronic HCV in combination with peginterferon.48,50  
A phase II noninferiority study evaluating the use of taribavirin (800 to 1600 mg daily) versus 
ribavirin (1000 to 1200 mg daily) in combination with peginterferon yielded results of lower 
SVR rates with taribavirin; however, it did prove to be noninferior to ribavirin (23 to 37%, 
respectively versus 44% with ribavirin, p=0.155).36,49 Lower rates of severe anemia were noted 
with taribavirin vs. ribavirin (4% vs. 27%).  
Subsequent phase III studies (VISER 1 and VISER 2) evaluated taribavirin (600 mg twice daily) 
compared with ribavirin (1000 to 1200 mg/day based on weight) in treatment naïve patients with 
all genotypes in combination with peginterferon alfa-2a. Results of these studies failed to 
demonstrate noninferiority of taribavirin to ribavirin in the intention-to-treat analysis. SVR rates 
were 38% with taribavirin and 52% with ribavirin in VISER 1 and 40% versus 55% in VISER 2, 
respectively. In both studies, taribavirin did have lower rates of anemia (5% vs. 24% and 6% vs. 
22%); however, in VISER 2, more patients receiving taribavirin experienced moderate to severe 
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diarrhea (29.5% vs. 15.7%, p<0.0001). Though these studies were powered based on phase II 
SVR rates, the authors concluded that noninferiority may not have been established due to 
suboptimal dosing of taribavirin. Because ribavirin is most appropriately dosed based on weight, 
the theory that taribavirin may prove more effective with weight-based dosing has yet to be 
proven.37,49 
An unpublished phase IIb study was initiated based on post-hoc findings that weight-based 
taribavirin may prove more effective than standard dosing. This study evaluated 275 treatment 
naïve patients with genotype 1 HCV. Taribavirin at dosages of 20, 25, or 30 mg/kg/day were 
compared with ribavirin in addition to peginterferon. End of treatment response rates after 48 
weeks of treatment were reported as 43.4%, 32.9%, 29.4% for taribavirin, respectively, and 
32.9% for ribavirin. Rates of anemia were also lower in the taribavirin group (13.4%, 15.7%, 
27.9% for taribavirin and 32.9% for ribavirin).49 The results of this study are promising and need 
to be confirmed in larger, well-designed studies.  
Protease Inhibitors 
Two protease inhibitors are in development targeted against chronic HCV.47 Boceprevir (SCH 
503034) and telaprevir (VX-950) are oral agents currently in phase III clinical trials in the U.S. 
Both antiviral therapies are reversible, selective NS3 protease inhibitors, which is an enzyme 
responsible for viral replication.51-53 Both agents have shown substantial reductions in viral load 
in phase I clinical studies. All studies thus far have been conducted in patients with genotype 1 
(Table 6).34-38 More recent studies have evaluated the use of these agents as a retreatment option 
for patients previously unable to achieve or maintain SVR.38,54 Additive and synergistic effects in 
viral reduction and SVR have been noted with the combination of peginterferon, ribavirin and a 
protease inhibitor. Additionally, combination therapy has decreased the emergence of resistance 
with these agents.51,55-56 Adverse events noted to be more common with telaprevir include rash 
and pruritis.51,53,55-56   
A phase I clinical study conducted in 26 patients with genotype 1, who were previous non-
responders to therapy, evaluated the safety and tolerability of boceprevir in combination with 
peginterferon alfa-2b.54 This randomized, open-label, crossover study evaluated 2 dosages of 
boceprevir over 3 dosing periods. One week of boceprevir monotherapy was followed by 
monotherapy with peginterferon alfa-2b for 2 weeks and then combination therapy of both 
agents for 2 weeks. A minimum 2 week washout period was incorporated between each dosing 
period. The two dosage regimens of boceprevir evaluated were 200 mg three times daily and 400 
mg three times daily. Peginterferon alfa-2b was administered at standard dosing of 1.5 µg/kg 
once weekly. Results of this study showed that boceprevir was well-tolerated. Combination 
therapy was associated with a higher incidence of headache, rigor and myalgia. Pharmacokinetic 
analyses showed only a slight increase in bioavailability for combination therapy as compared 
with low-dose boceprevir monotherapy, and no increase in area-under-the-curve (AUC) was 
noted during combination therapy with high-dose boceprevir as compared to monotherapy.  
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A recently published international phase II study evaluated the use of telaprevir in genotype 1 
patients previously not achieving or maintaining SVR with prior therapy.38 The study was a 
randomized, stratified study evaluating one of four possible treatment regimens on achievement 
of SVR. Telaprevir was administered as a single initial oral dose of 1125 mg followed by 750 mg 
every 8 hours, peginterferon alfa-2a was dosed at 180 µg subcutaneously weekly, and ribavirin 
was dosed according to weight (1000 mg/day for weight <75 kg and 1200 mg/day if weight ≥75 
kg). One group (T12PR24) received telaprevir in combination with peginterferon alfa-2a and 
ribavirin for 12 weeks followed by placebo, peginterferon alfa-2a and ribavirin for an additional 
12 weeks. Another group (T24PR48) received telaprevir in combination with peginterferon alfa-
2a with ribavirin for 24 weeks followed by peginterferon alfa-2a and ribavirin for an additional 
24 weeks. The T24P24 group received telaprevir and peginterferon alfa-2a for 24 weeks, and the 
PR48 (control) group received placebo plus peginterferon alfa-2a in combination with ribavirin 
for 24 weeks, followed by peginterferon alfa-2a and ribavirin for an additional 24 weeks.  The 
majority of patients were white males, average age 51 years, who had previously not responded 
to prior therapy.  
Results showed SVR was statistically higher in each telaprevir group. Additionally, SVR rates 
were higher among patients who previously experienced relapse vs. nonresponders. Logistic 
regression analyses revealed SVR was associated with assignment to the shorter telaprevir 
courses combined with longer peginterferon/ribavirin, previously undetectable HCV RNA levels 
and low baseline viral load. Maculopapular rash and pruritis were more common in groups that 
received telaprevir. The median time to rash appearance was 7 to 28 days, and 18 patients (5%) 
in the telaprevir group discontinued treatment due to rash. Additionally, patients in the telaprevir 
group were more likely to discontinue treatment due to adverse effects, with skin disorders the 
most common reason for discontinuation. A decrease in hemoglobin levels was observed more 
frequently in the telaprevir-based groups vs. controls.38 
Overall, protease inhibitors hold promise in treating patients with chronic HCV. To date, all 
studies have focused on genotype 1, and more studies are beginning to evaluate the use of 
protease inhibitors as an option for retreatment vs. initial therapy. Broader patient populations 
and larger studies in the future will help to clarify the exact role of these agents in the treatment 
of HCV.  
Special Considerations 
Human Immunodeficiency Virus 
Patients co-infected with HIV and HCV represent a unique challenge to the treatment of HCV. A 
large number of patients infected with HIV are also infected or become infected with HCV, 
leading to increased susceptibility to adverse treatment and disease effects, resulting in higher 
morbidity and mortality.57 When patients with HIV are infected with HCV, they are less likely to 
spontaneously clear the virus, and the rate of liver disease progression may be accelerated.57-60 
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Liver-related hospitalizations tripled for patients co-infected with HIV from 1994 to 2001.6 
Clinical judgment needs to be utilized regarding which co-infected patients to treat. Risk of 
serious liver disease should be weighed against the risk of morbidity from adverse events and 
anticipated treatment response.7  
Peginterferon alfa in combination with ribavirin at standard dosages for a duration of 48 weeks is 
the recommended treatment for  HIV/HCV co-infected patients.7,57,59-60 Two meta-analyses of 6 
to 7 randomized, controlled trials found that peginterferon in combination with ribavirin was 
shown to produce a higher probability of achieving SVR as compared to treatment with 
interferon or peginterferon monotherapy.57,60 Patients treated with peginterferon and ribavirin 
were less likely to withdraw from treatment and develop hepatic decompensation.57 SVR rates 
for patients with HIV/HCV genotype 1/4 were found to be 25% vs. 54% for genotypes 2/3.60 A 
clinical outcome study of HIV/HCV co-infected patients in Spain showed that patients who 
achieved SVR had a lower rate of all-cause mortality, liver-related death and liver 
decompensation (p<0.05).59  
Adverse effects and drug interactions with ribavirin are especially concerning in patients co-
infected with HIV/HCV. Anemia and neutropenia are of particular concern and require careful 
monitoring, dosage adjustments, and supplemental therapy as appropriate. Drug interactions with 
antiretroviral therapy also require careful evaluation. Ribavirin can increase the activity and 
toxicity of didanosine and other nucleoside reverse transcriptase inhibitors (NRTIs), with the 
potential to cause mitochondrial toxicity and lactic acidosis.61 Other NRTIs that may interact via 
this mechanism include abacavir, lamivudine, stavudine, zalcitabine and zidovudine. For this 
reason, concomitant administration of didanosine and ribavirin is contraindicated and the other 
NRTIs should be used cautiously and only if the benefit of treatment outweighs the risk.  
Ribavirin can also reduce the effectiveness of stavudine and zidovudine.18 Additive 
pharmacodynamic drug interactions may also result in increased adverse effects, including the 
risk of anemia with coadministration of ribavirin and zidovudine, and the risk of hepatotoxicity 
with the administration of ribavirin and lamivudine or zidovudine. Reduced adherence due to 
drug interactions, adverse effects and poor tolerability should be assessed in every patient.  
Reducing and/or extending treatment durations and appropriate management of non-responders 
(treatment algorithms) in patients co-infected with HIV/HCV need to be more adequately studied 
before strong recommendations can be made in this population.62 
End Stage Renal Disease 
Infection with HCV is higher among patients with end-stage renal disease (ESRD). The approach 
to treatment in ESRD is different than in patients with normal renal function. Altered 
pharmacokinetics and drug-related toxicities are concerns.63 Both interferon and ribavirin are 
renally eliminated. Because ribavirin is not recommended for use in patients with moderate renal 
function impairment (CrCl <50 mL/min), most studies have evaluated the use of interferon 
monotherapy in patients with compromised renal function.18,64 Ribavirin is not removed by 
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hemodialysis. In renal dysfunction, the half-life of interferon and peginterferon is increased by as 
much as 40% and the AUC is also increased by as much as 90% when compared to patients with 
normal renal function. For this reason, dosage reductions in patients with moderate to severe 
renal impairment are necessary. Important considerations for therapy in patients with ESRD 
include tolerance to adverse effects and the potential for increased toxicity, reduced adherence 
and treatment response.63 
AASLD guidelines do recommend as class IIa recommendations careful monitoring and 
treatment at reduced dosages of peginterferon (2a: 135 µg/week; 2b: 1µg/kg/week) and ribavirin 
(200-800 mg/day) in patients with severe kidney disease, and a IIb recommendation that dialysis 
patients be considered for treatment with standard interferon or reduced dose peginterferon. 
Ribavirin can be added at a markedly reduced dosage with careful monitoring for adverse 
effects, but it is a class IIb recommendation. The limited number of studies cited in support of 
using low-dose ribavirin in any setting of renal dysfunction (CrCl < 50 mL/min) was associated 
with significant adverse effects, including hemolytic anemia and often involved the use of 
growth factors.7 
Few prospective clinical studies exist evaluating the treatment of chronic HCV in patients with 
ESRD. Studies of treatment with conventional interferon monotherapy often included a very 
small number of patients and poor study design (observational studies). SVR rates were found to 
be lower in treatment-naïve patients with normal renal function (13 to 19%) as compared to 
patients with renal impairment (33 to 37%), which indicate interferon monotherapy may be more 
effective in patients with ESRD.63 Studies of peginterferon monotherapy in patients with ESRD 
have resulted in reduced tolerability and SVR rates ranging from 12 to 75%. Comparative studies 
are needed to determine which therapy is associated with better treatment response and better 
tolerability.63-64 A meta-analysis of 20 prospective studies of interferon-based (non-pegylated) 
treatment in patients with ESRD and HCV revealed several characteristics associated with a 
higher likelihood of achieving SVR, including patients receiving a larger dose of interferon, a 
longer duration of treatment, full completion of treatment, female gender, lower HCV RNA and 
virologic response.65 More recent studies have begun focusing on the use of low-dose ribavirin in 
patients with ESRD often based on serum ribavirin concentrations; however, once again stronger 
evidence is needed prior to implementing this therapeutic strategy into routine practice.63-64,66  
Injection Drug Abuse 
Special considerations are necessary before initiating treatment for chronic HCV in patients with 
a history of injection drug abuse. These include evaluating the benefits of treatment, the risk of 
reinfection, comorbid psychiatric illness and adherence to therapy and monitoring, among 
others.7,67 Although some data indicates a lower rate of SVR is achieved in patients with IDU, 
the data is conflicting.67-68 A recent retrospective study showed no significant differences in 
efficacy in adherent patients with active IDU.68 The pharmacokinetics of methadone are not 
significantly altered by peginterferon.69 A study conducted in treatment of acute HCV in IDU 
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has shown promising results on SVR and greater compliance with a short treatment regimen. 
This was a prospective, open-label non-randomized study in 23 patients with IDU and acute 
HCV who received peginterferon alfa-2b for 12 weeks. Results showed an overall SVR in 17 
patients (74%).70 
Pregnancy 
Routine screening of all pregnant women for HCV infection is not recommended by AASLD or 
the American College of Obstetricians and Gynecologists.7,71 No evidence suggests that HCV 
infection will adversely affect pregnancy outcomes in terms of fetal or obstetric complications.72 
Additionally, no specific agencies have guidelines for treatment or monitoring of HCV in 
pregnancy. Given that ribavirin is absolutely contraindicated in pregnant women and strict 
precautions must be undertaken to prevent pregnancy in women of child-bearing age, treatment 
must occur well before conception or after delivery. Because ribavirin has a multiple dose half 
life of 12 days, it can persist for up to 6 months in nonplasma compartments. For this reason, 
pregnancy must be avoided both during treatment with ribavirin and for 6 months following 
treatment in female patients and female partners of male patients.18  
From 2003 to 2009, 351 pregnancies have been tracked in the Ribavirin Pregnancy Registry, 6 of 
which described birth outcomes with defects. Three of these exposures were direct exposure and 
3 were as a result of indirect ribavirin exposure. Specific defects included 1 cardiac defect, 2 
cases of torticollis, 1 case of glucose-6-phosphate dehydrogenase deficiency, 1 case of 
hypospadias and a case of polydactyly. A larger sample of patients from the registry is planned 
to assess the relative risk of birth defects associated with ribavirin.73 Interferon monotherapy has 
not been well-studied in pregnancy, and interferons are classified as Pregnancy Category C. 
Peginterferon alfa-2a contains benzyl alcohol. Interferons should be considered to have 
abortifacient potential.19-20  
Pediatrics 
The emphasis on children with HCV is focused on promoting awareness, diagnosis and initiating 
early treatment. Since the implementation of routine blood screening, vertical transmission has 
replaced transfusion-associated HCV as the most common mode of HCV transmission in 
pediatrics the U.S.7 Maternal viral load is the most important factor associated with vertical 
transmission.74 Most children with HCV are asymptomatic, as in adults, and the standard therapy 
is peginterferon in combination with ribavirin. Peginterferon alfa-2b is FDA approved for 
patients’ ages 3 years and older and is dosed at 60 µg/m2 subcutaneously weekly in combination 
with ribavirin 15 mg/kg daily. A treatment duration of 48 weeks is recommended as a class I 
recommendation by AASLD regardless of genotype.7 Treatment should be considered in the 
same manner as in adults, with additional consideration given to patient age, level in school and 
stress.  
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Most children who undergo treatment tolerate therapy well, but adverse effects are commonly 
reported such as flu-like symptoms, pyrexia, headache, vomiting, fatigue and neutropenia.18,75-77 
Studies have shown that pediatric patients, especially adolescents, who received ribavirin 
experienced suicidal ideation or attempted suicide more frequently than in adults (2.4% vs. 1%). 
This occurred both during treatment and follow-up. Additionally, weight loss (mean percentile 
decrease of 13%) and decreased linear growth (mean percentile decrease of 9%) occurred in 
pediatric patients treated for 48 weeks, which was mostly reversible during the 6 months after 
treatment.18  
An open label, noncontrolled study conducted by Wirth et al. was one of the earliest studies on 
the use of peginterferon alfa in the treatment of HCV in children.76 In this study, 62 children, 
ages 2 to 17 years, were administered peginterferon alfa-2b, 1.5 µg/kg subcutaneously weekly in 
combination with ribavirin 15 mg/kg daily in two divided doses for 48 weeks. The majority of 
patients (75.8%) had genotype 1. Overall rates of SVR were 59%, including 47.8% of patients 
with genotype 1 HCV and 100% of genotypes 2/3 (p=0.0003). Adverse events frequently 
reported included leucopenia (75.4%), neutropenia (55.7%), flu-like symptoms (82%), and fever 
(51%). Other events included weight loss (19.7%), and temporary mood swings (14.8%).    
A more recent open-label study was conducted in 30 children, ages 3 to 16 years, to evaluate 
peginterferon alfa-2b, 1 µg/kg subcutaneously weekly in combination with ribavirin 15 mg/kg 
daily.77 In this study, children with genotype 1 were treated for 48 weeks and those with 
genotypes 2/3 were treated for 24 weeks. Most patients had genotype 1, were treatment naïve 
and acquired HCV via vertical transmission. Overall, SVR was attained in 50% of patients. 
Adverse effects included flu-like symptoms, fever, fatigue, headache, decreased appetite and 
weight loss. Body weight decreased in 20% of children (>5% weight loss occurred in 7%) but 
returned to baseline by week 48. Growth was reduced by 1.6 cm in 22 of 26 children compared 
with the growth velocity 50th percentile for age and sex but was entirely normal in the 6 months 
following treatment. Neutropenia (neutrophils < 1000 x 109 cells/L) occurred in 9 patients 
necessitating reductions in dosing. Further studies in children are needed to clarify treatment 
duration in genotypes 2/3 and long-term clinical outcomes.  
Conclusion 
Treatment of patients with chronic HCV should be individualized with consideration given to 
prevention of transmission, risk factor modification as appropriate, adverse events and 
tolerability, adherence, and avoidance of complications. Current practice guidelines published by 
the AASLD represent the evidence-based standard for management of HCV. Currently, 
peginterferon and ribavirin represent the standard of care for treatment of chronic HCV. A 
surrogate marker for clinical outcomes in HCV is sustained virologic response. Of the two 
currently available pegylated interferons, both are equally efficacious in attaining SVR. Duration 
of therapy is guided by HCV genotype and virologic response. Because of the high rate of RVR 
and SVR, genotypes 2 and 3 can be treated for 24 weeks. Genotypes 1 and 4 require 48 weeks 
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duration of treatment. In all patients undergoing treatment, appropriate monitoring for serious 
treatment-related adverse effects must be conducted. Hematologic abnormalities, including 
anemia and neutropenia may require a reduction in dosage or withdrawal from treatment. New 
therapies in development for treatment of HCV have the potential to reduce adverse effects and 
improve outcomes. Special populations, including patients co-infected with HIV, patients with 
severe chronic kidney disease, injection drug users, pregnancy and pediatric patients should be 
closely monitored to prevent HCV related morbidity and mortality.   
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Table 1. Selected AASLD Guideline Recommendations for Management of Hepatitis C7 
AASLD = American Association for the Study of Liver Diseases. 
aThe AASLD classifications of recommendations are as follows:  
The AASLD classifications of recommendations are as follows: Class I = conditions for 
which there is evidence and/or general agreement that a given diagnostic evaluation 
procedure or treatment is beneficial, useful, and effective; II = conditions for which there 
is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a 
diagnostic evaluation, procedure or treatment; IIa = weight of evidence/opinion is in 
favor of usefulness/efficacy; IIb = usefulness/efficacy is less well established by 
evidence/opinion; III = conditions for which there is evidence and/or general agreement 
that a diagnostic evaluation, procedure/treatment is not useful/effective and in some cases 
may be harmful. 
The AASLD levels of evidence are as follows: A = data derived from multiple 
randomized clinical trials or meta-analyses; B = data derived from a single randomized 
trial, or non-randomized studies; C = only consensus opinion of experts, case studies, or 
standard-of-care. 
Table 2. HCV Risk Factors1-3,7,9-10 
Table 3. Diagnosis of HCV3,7 
Table 4. Definitions of Treatment Responses in HCV7 
Table 5. Clinical Trials of Therapies for the Treatment of Hepatitis C23-33 
            RBV = ribavirin 
 Peg-IFN alfa-2a = peginterferon alfa-2a 
 Peg-IFN alfa-2b = peginterferon alfa-2b 
 Peg-IFN = peginterferon 
aComplete treatment regimens with dosing are provided in text 
bPercentages were rounded to the nearest whole number 
cSlow Responders: HCV RNA positive at 12 weeks 
dSlow Responders: 2-log reduction in HCV RNA and undetectable levels at week 24 
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eTreatment duration was 24 weeks 
fTreatment duration was 72 weeks 
gOverall RVR occurred in 302/428 patients prior to randomization 
 
Table 6. Clinical Trials of Alternative and Investigational Therapies for the Treatment of 
Hepatitis C34-38 
 
RBV = ribavirin 
 Peg-IFN alfa-2a = peginterferon alfa-2a 
 Peg-IFN alfa-2b = peginterferon alfa-2b 
 Alb-IFN alfa-2b = albinterferon alfa-2b 
 Ta-RBV = taribavirin 
aComplete treatment regimens with dosing are provided in text 
bPercentages were rounded to the nearest whole number 
cDependent upon HCV genotype (genotype 2/3: duration 24 weeks; non 2/3: duration 48 
weeks) 
dMajority of patients discontinued as a result of meeting a stopping rule, including 
virologic breakthrough, nonresponse at week 4, 12 or 24




Table 1. Selected AASLD Guideline Recommendations for Management of Hepatitis C7 
Intervention  AASLD Class, Level of Evidencea 
Treatment decisions should be individualized based on the severity of liver disease, the potential for serious side  
effects, the likelihood of treatment response, the presence of comorbid conditions, and willingness to undergo treatment. IIa, C 
 
The optimal therapy for chronic HCV infection is the combination of peginterferon alfa and ribavirin. I, A 
 
HCV RNA should be tested at the initiation of or shortly before treatment and at week 12 of therapy.  I, A 
Genotypes 1 and 4 HCV Infection 
Treatment with peginterferon plus ribavirin should be planned for 48 weeks; the dose for peginterferon alfa-2a is  
180 µg subcutaneously per week together with ribavirin using doses of 1000 mg for those <75 kg in weight and 1200 mg  
for those >75 kg; the dose for peginterferon alfa-2b is 1.5 µg/kg subcutaneously per week together with ribavirin using  
doses of 800 mg for those weighing <65 kg; 1000 mg for those weighing >65 kg to 85 kg, 1200 mg for >85 kg to 105 kg,  
and 1400 mg for >105 kg. I, A 
 
Treatment may be discontinued in patients who do not achieve an EVR.  I, A 
Patients who do not achieve a complete EVR should be re-tested at week 24, and if HCV RNA remains positive,  
treatment should be discontinued.  I, A 
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Patients with genotype 1 infection whose treatment continues through 48 to 72 weeks and whose measurement of HCV is  
negative at the end of treatment should be retested for HCV RNA 24 weeks later to evaluate for SVR. I, A 
 
Genotype 2 or Genotype 3 HCV Infection 
Treatment with peginterferon plus ribavirin should be administered for 24 weeks, using a ribavirin dose of 800 mg. I, A 
Genotype 2 or Genotype 3 HCV Infection 
Patients whose treatment continues through 24 weeks and whose measurement of HCV RNA is negative should be retested  
for HCV RNA 24 weeks later to evaluate for SVR.  I, A 
 
Retreatment with peginterferon plus ribavirin can be considered for non-responders or relapsers who have previously been  
treated with non-pegylated interferon with or without ribavirin, or with peginterferon monotherapy, particularly if they  
have bridging fibrosis or cirrhosis.  IIa, B 
 
Retreatment with peginterferon plus ribavirin in patients who did not achieve SVR after a prior full course of  
peginterferon plus ribavirin is not recommended, even if a different type of peginterferon is administered. For relapsers: III, C; 
  For non-responders: III, B 
Initial treatment of hepatitis C in most HIV-infected patients should be peginterferon plus ribavirin for 48 weeks at doses  
recommended for HCV mono-infected patients.  I, A 




Children aged 2-17 years who are infected with HCV should be considered appropriate candidates for treatment using 
 the same criteria as that used for adults.  IIa, B 
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Table 2. HCV Risk Factors1-3,7,9-10    
Risk Factor Explanation Recommendation 
Injection drug use Most common route of exposure Screen 
Blood or blood component prior to 1992 Routine blood screening implemented in 1992 Screen 
Healthcare exposure Following needle stick injury or mucosal exposure of HCV positive blood Screen 
Patients who have ever been on chronic hemodialysis Higher prevalence of HCV infection Screen 
Patients with HIV Higher prevalence of HCV infection Screen 
Children of HCV-infected mothers <5% of children acquire infection; not linked to breastfeeding Screen 
Current partners of HCV-infected persons Risk with monogamous sexual partners is <1% Screen for reassurance 
Persons with multiple sexual partners Higher prevalence of HCV with multiple partners Safe sexual practices 
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Table 3 . Diagnosis of HCV3,7 
Anti-RNA (EIA) HCV RNA Interpretation Follow-up 
Positive Positive Acute or chronic infection  Assess for therapy 
Positive Negative Acute infection with low level viremia or resolution of infection Consider repeat testing in 4 to 6 
months; evaluate signs/symptoms 
Negative Positive Possible false-positive HCV RNA, acute infection or inadequate immune response Consider repeat testing in 4 to 6 
months 
Negative Negative Absence of infection Assess for at-risk behaviors and 
development of signs/symptoms 
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Table 4. Definitions of Treatment Responses in HCV7 
Response Definition 
Rapid virologic response (RVR) Undetectable HCV RNA at week 4 of therapy 
Early virologic response (EVR) At least a 2-log reduction in HCV RNA by 12 weeks of 
therapy 
End-of-treatment response (ETR) No detectable HCV RNA at the end of therapy 
Sustained virologic response (SVR) No detectable HCV RNA at the conclusion of treatment and 
24 weeks after discontinuation of therapy 
Breakthrough Reappearance of HCV RNA while still receiving therapy 
Relapse Reappearance of HCV RNA after discontinuation of therapy 
Nonresponder Failure to achieve undetectable HCV RNA after 24 weeks 
of therapy 
Partial responder At least a 2-log reduction in HCV RNA but never reaches 
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Table 5. Clinical Trials of Therapies for the Treatment of Hepatitis C23-33 
Author Genotype Study Treatmenta No. of Patients Duration (wks)  RVR/EVRb SVRb Relapse/Discontinuationb 
    
Comparative Efficacy of Pegylated Interferons 
Di Bisceglie et al.23 1 Peg-IFN alfa-2a + RBV  380 12 66 EVR 
  vs. Peg-IFN alfa-2b + RBV   63 EVR 
   
Escudero et al.24 1 – 4 Peg-IFN alfa-2a + RBV  183 24  66 
  vs. Peg-IFN alfa-2b + RBV    62 
  
McHutchison et al.25 1 Standard Peg-IFN alfa-2b + RBV 3070 48  40 
  Low-dose Peg-IFN alfa-2b + RBV    38 
  Standard Peg-IFN alfa-2a    41  
Duration of Therapy According to Genotype 
Berg et al.26 1 Peg-IFN alfa-2a + RBV 455 48  53 29 / 24 
      17c 
    72  54 21 / 41 
      29c 
 
Pearlman et al.27  1 Peg-IFN alfa-2b + RBV 101 24  18d 59 / 14 
    48  38d 20 / 15 
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Mangia et al.28  1 Peg-IFN alfa-2a or  696 24 Standard vs.   Standard: 19 / 10 
  Peg-IFN alfa-2b + RBV  48 Variable (SVR): Variable: 19 / 13 
    72 Week 4 (-): 87 vs. 77e 
     Week 8 (-): 70 vs. 72 
     Week 12 (-): 38 vs. 63f 
  
Ferenci et al.29  1/4 Peg-IFN alfa-2a + RBV 516 24 29 77 11 / 1 
 
Shiffman et al.30 2/3 Peg-IFN alfa-2a + RBV 1469 16 67 / 89 65 31 / 4 
    24 64 / 89 76 18 / 5  
Lagging et al.31 2/3 Peg-IFN alfa-2a + RBV 382 12  59 33 / 1 
    24  78 12 / 10 
 
Dalgard et al.32 2/3 Peg-IFN alfa-2b + RBV 428 14 71g  81 11 / 6 
    24  91  5 / 21 
 
Nguyen et al.33 6 Peg-IFN + RBV 35 24  39 
    48  75  
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Table 6. Clinical Trials of Alternative and Investigational Therapies for the Treatment of Hepatitis C34-38 
Author Population/Genotype Study Treatmenta No. of Patients Duration (wks)  SVRb Relapse/Discontinuationb 
Albinterferon  
Zeuzem et al.34 Treatment naïve/1 Alb-IFN alfa-2b 900 µg Q 2 weeks vs. 458 48 59 29 / 19 
  Alb-IFN alfa-2b 1200 µg Q 2 weeks vs.      56 31 / 29 
  Alb-IFN alfa-2b 1200 µg Q 4 weeks vs.      51 28 / 17 
  Peg-IFN alfa-2a      58 29 / 13 
Bain et al.35  Treatment naïve /2/3 Alb-IFN alfa-2b Q 2 wks vs. 43 24 62 28 / 38 
  Alb-IFN alfa-2b Q 4 wks 77 19 / 14 
Taribavirin  
Gish et al.36  Treatment naïve Ta-RBV 1200 mg + Peg-IFN alfa-2a vs. 180 24-48c 37  42 / 25 
  Ta-RBV 800 mg + Peg-IFN alfa-2a vs. 23 64 / 24 
  Ta-RBV 1600 mg + Peg-IFN alfa-2a vs. 29 57 / 30  
  RBV + Peg-IFN alfa-2a 44 41 / 21 
Marcellin et al.37 Treatment naïve Ta-RBV + Peg-IFN alfa-2a vs. 962 24-48c  40 35 / 26 
  RBV + Peg-IFN alfa-2a     55 18 / 26 
Protease Inhibitors 
McHutchison et al.38  Previously treated/1 T12PR24a 453  Varied  51 30 / 25d  
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  T24PR48     53 13 / 51d 
  T24P24     24 53 / 48d 
  PR48     14 53 / 68d 




Figure 1. U.S. Incidence of Acute Hepatitis C, 1980-20075 
 
 
